{"id":291,"date":"2026-10-03T09:35:25","date_gmt":"2026-10-03T16:35:25","guid":{"rendered":"https:\/\/atlasperformance.us\/?page_id=291"},"modified":"2026-10-03T09:35:26","modified_gmt":"2026-10-03T16:35:26","slug":"tesamorelin","status":"publish","type":"page","link":"https:\/\/atlasperformance.us\/es\/tesamorelin\/","title":{"rendered":"The Tesamorelin Research Deep-Dive"},"content":{"rendered":"\n<style>\n  .wrap { max-width: 720px; margin: 0 auto; padding: 48px 24px 64px; background:#0b1f3a; color:#f5f2e9; font-family: Georgia, 'Times New Roman', serif; }\n  .brand { font-family: Arial, sans-serif; font-size: 13px; letter-spacing: 5px; color: #c9a227; text-align:center; margin-bottom: 18px; }\n  .wrap h1 { text-align:center; font-size: 40px; line-height: 1.25; margin: 0 0 12px; font-weight: normal; color:#f5f2e9; }\n  .wrap h1 .gold { color:#c9a227; }\n  .sub { text-align:center; font-family: Arial, sans-serif; font-size: 17px; line-height: 1.6; color:#d8d4c4; margin-bottom: 36px; }\n  .card { background:#ffffff; color:#1a1a1a; border-radius: 10px; padding: 36px 36px 30px; margin-bottom: 28px; }\n  .card h2 { font-family: Arial, sans-serif; font-size: 20px; margin: 0 0 16px; color:#0b1f3a; }\n  .card ul { font-family: Arial, sans-serif; font-size: 16px; line-height: 1.9; margin: 0; padding-left: 22px; }\n  .card li::marker { color:#c9a227; }\n  .formbox { background:#12294d; border:1px solid #c9a227; border-radius: 10px; padding: 36px; text-align:center; }\n  .formbox h2 { font-family: Arial, sans-serif; font-size: 22px; margin: 0 0 8px; color:#f5f2e9; }\n  .formbox p { font-family: Arial, sans-serif; font-size: 15px; color:#d8d4c4; line-height:1.6; margin: 0 0 20px; }\n  .fine { font-family: Arial, sans-serif; font-size: 12.5px; line-height: 1.7; color:#9a958a; text-align:center; margin-top: 28px; }\n<\/style>\n<div class=\"wrap\">\n  <div class=\"brand\">ATLAS PERFORMANCE<\/div>\n  <h1>The Tesamorelin<br><span class=\"gold\">Research Deep-Dive<\/span><\/h1>\n  <p class=\"sub\">An FDA-approved peptide &mdash; with a label that tells the real story.<br>A free 5-page PDF &mdash; no hype, just the studies.<\/p>\n  <div class=\"card\">\n    <h2>What&#8217;s inside<\/h2>\n    <ul>\n      <li><strong>What tesamorelin is<\/strong> &mdash; the stabilized GHRH analog, and the problem it was built for<\/li>\n      <li><strong>The Phase 3 trial record<\/strong> &mdash; 816 patients, 14&ndash;18% visceral-fat reduction, in plain English<\/li>\n      <li><strong>Where the label stops<\/strong> &mdash; what&#8217;s not approved, stated honestly<\/li>\n      <li><strong>Safety notes<\/strong> &mdash; what the trials showed, including the unknowns<\/li>\n      <li><strong>The timeline<\/strong> &mdash; from 2005 Phase 2 data to the 2010 FDA approval and beyond<\/li>\n    <\/ul>\n  <\/div>\n  <p class=\"fine\">Educational research summary only &mdash; not medical advice.<br>All Atlas Performance products are intended for research and identification purposes only.<\/p>\n<\/div>\n\n\n<p>[tesa_form]<\/p>\n\n\n\n<p class=\"fine\" style=\"max-width:720px;margin-left:auto;margin-right:auto;\">All products sold on this website are intended for research and identification purposes only.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ATLAS PERFORMANCE The TesamorelinResearch Deep-Dive An FDA-approved peptide &mdash; with a label that tells the real story.A free 5-page PDF &mdash; no hype, just the studies. What&#8217;s inside What tesamorelin is &mdash; the stabilized GHRH analog, and the problem it was built for The Phase 3 trial record &mdash; 816 patients, 14&ndash;18% visceral-fat reduction, in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-291","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/atlasperformance.us\/es\/wp-json\/wp\/v2\/pages\/291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atlasperformance.us\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/atlasperformance.us\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/atlasperformance.us\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atlasperformance.us\/es\/wp-json\/wp\/v2\/comments?post=291"}],"version-history":[{"count":1,"href":"https:\/\/atlasperformance.us\/es\/wp-json\/wp\/v2\/pages\/291\/revisions"}],"predecessor-version":[{"id":292,"href":"https:\/\/atlasperformance.us\/es\/wp-json\/wp\/v2\/pages\/291\/revisions\/292"}],"wp:attachment":[{"href":"https:\/\/atlasperformance.us\/es\/wp-json\/wp\/v2\/media?parent=291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}